The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases
Open accessAbstract
Emerging viruses such as HIV, dengue, influenza A, SARS coronavirus, Ebola, and other viruses pose a significant threat to human health. Majority of these viruses are responsible for the outbreaks of pathogenic lethal infections. To date, there are no effective therapeutic strategies available for the prophylaxis and treatment of these infections. Chloroquine analogs have been used for decades as the primary and most successful drugs against malaria. Concomitant with the emergence of chloroquine-resistant Plasmodium strains and a subsequent decrease in the use as antimalarial drugs, other applications of the analogs have been investigated. Since the analogs have interesting biochemical properties, these drugs are found to be effective against a wide variety of viral infections. As antiviral action, the analogs have been shown to inhibit acidification of endosome during the events of replication and infection. Moreover, immunomodulatory effects of analogs have been beneficial to patients with severe inflammatory complications of several viral diseases. Interestingly, one of the successful targeting strategies is the inhibition of HIV replication by the analogs in vitro which are being tested in several clinical trials. This review focuses on the potentialities of chloroquine analogs for the treatment of endosomal low pH dependent emerging viral diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Effects of chloroquine on viral infections: an old drug against today's diseases
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., & Cauda, R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00806-5 · Cited by 1,268
Tumor necrosis factor: a pleiotropic cytokine and therapuetic target
Tracey, M. D., & Cerami, P. D. (1994) · Annual Review of Medicine · doi:10.1146/annurev.med.45.1.491 · Cited by 1,063
Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection
Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P., & Cunningham, J. M. (2005) · Science · doi:10.1126/science.1110656 · Cited by 826
Neopterin as a Marker for Immune System Activation
Murr, C., Widner, B., Wirleitner, B., & Fuchs, D. (2002) · Current Drug Metabolism · doi:10.2174/1389200024605082 · Cited by 738
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 736
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 649
Cited by
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper
Boettler, T., Newsome, P. N., Mondelli, M. U., Maticic, M., Cordero, E., Cornberg, M., & Berg, T. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100113 · Cited by 477
Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19
Yang, N., & Shen, H.-M. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45498 · Cited by 412
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
Li, Z., Li, X., Huang, Y.-Y., Wu, Y., Liu, R., Zhou, L., Lin, Y., Wu, D., Zhang, L., Liu, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010470117 · Cited by 255
Malaria and COVID-19: unmasking their ties
Hussein, M. I. H., Albashir, A. A. D., Elawad, O. A. M. A., & Homeida, A. (2020) · Malaria Journal · doi:10.1186/s12936-020-03541-w · Cited by 156
Metadata
- Authors
- Al-Bari, M. A. A.
- Venue
- Pharmacology Research & Perspectives
- Publisher
- Wiley
- Published
- 2017-01-23
- Volume
- 5
- Issue
- 1
- Pages
- e00293
- ISSN
- 2052-1707 (ISSN-L)
- OpenAlex
- W2580356750
- Cited by
- 382
- References
- 90
- FWCI
- 25.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. https://app.cochat.ai/papers/10.1002/prp2.293
- The paper
- Al-Bari, M. A. A. (2017). Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.293
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
